Top 5 Pfizer Government Contracts

Pfizer has been a prime developer and distributor of medicinal relief for over 100 years. It is also a reliable contractor for different federal agencies in the United States, offering drugs and vaccines for common and rare diseases. Get to know the top government contracts won by Pfizer Inc. here.

What are the top Pfizer government contracts?

1. US Army Awarded Pfizer the Contract to Produce PAXLOVID, $5.29 Billion

• Year: 2021
• Federal agency: US Army Contracting Command
• Contract type: Firm-fixed-price
• Contract duration: 1 year and 4 months

The US Army Contracting Command (ACC) awarded Pfizer Inc. the firm-fixed-price contract to produce the oral protease drug PAXLOVID, with a budget of $5.29 billion. Under the contract, Pfizer will develop and deliver 10 million doses of the oral drug for the US government until March 31, 2023.

 

PAXLOVID is an antiviral oral drug used to treat COVID-19 patients from progressing to more severe symptoms of the virus. It is a combination of ritonavir and nirmatrelvir, two protease inhibitors that work together to keep the virus from growing and spreading inside the body.

 

Pfizer’s interim analysis in 2021 revealed that PAXLOVID reduced the risk of COVID-19-related hospitalization and death by 89%, compared to non-hospital and placebo treatments for high-risk adult patients.

 

PAXLOVID has been approved by the Food and Drug Administration (FDA) for conditional emergency use in the United States and 70 other countries. The Emergency Use Authorization (EUA) also authorized the emergency use of PAXLOVID to treat mild-to-moderate COVID-19 patients aged 12 years and older to prevent hospitalization and complications.

 

2. Pfizer Won the Modification Contract for Producing Additional PAXLOVID Courses, $442 Million

• Year: 2022
• Federal agency: US Army
• Contract type: Modification
• Contract duration: 1 year and 2 months

Pfizer Inc. was awarded the modification contract for producing and supplying PAXLOVID  for the US Army. The contract is valued at $442 million and accompanies the previous PAXLOVID agreement.

 

Pfizer is contracted to supply an additional 835,000 courses of PAXLOVID to the US Army until March 31, 2023. Work was executed in New York City, with the ACC funding Pfizer Inc. the contract value at the time of awarding.

 

3. Pfizer Secured Two More Modification Contracts for PAXLOVID, a Total of $6.75 Billion

• Year: 2022
• Federal agency: US Army Contracting Command
• Contract type: Modification

Months after the previous contract, Pfizer secured two more modification agreements from the ACC to supply more courses of PAXLOVID.

 

On September 7, 2022, Pfizer was funded $4.8 billion to supply PAXLOVID to the ACC in Aberdeen Proving Ground, Maryland. The order period for the antiviral oral drugs will end on March 31, 2023.

 

Subsequently, Pfizer was awarded another modification contract by the ACC to produce and deliver a new batch of 3.7 million courses of PAXLOVID to the US government on December 13, 2022. Pfizer was given a budget of $1.9 billion to start delivering the additional PAXLOVID doses in 2023 and is expected to fulfill the contract by December 31, 2028.

 

4. US Army Granted Pfizer the Contract to Manufacture, Store, and Deliver mRNA COVID-19 Vaccines, $3.2 Billion

• Year: 2022
• Federal agency: US Army Contracting Command
• Contract type: Firm-fixed-price
• Contract duration: 11 months

Pfizer, together with BioNTech SE, secured the firm-fixed-price agreement to manufacture, store, and deliver mRNA COVID-19 vaccines. ACC funded the awardees with a contract value of $3.2 billion to distribute 105 million doses of the vaccine to communities, healthcare providers, local healthcare departments, and federal government agencies.

 

Under the contract, the US government has the option to procure an additional 195 million doses, bringing the total number of delivered vaccine doses to 300 million. Pfizer is committed to this contract until May 31, 2023.

 

5. US Army Procured Additional COVID-19 Doses from Pfizer, $3.5 Billion, followed by a $2 Billion worth modification deal

• Year: 2021
• Federal agency: US Army Contracting Command
• Contract type: Firm-fixed-price
• Contract duration: 1 year and four months

Pfizer secured a firm-fixed-price contract to produce a total of 500 million COVID-19 vaccine doses on July 30, 2021. The pharmaceutical company was given a budget of  $3.5 billion–through US Army and fiscal 2021 research and development funds–to distribute the vaccines to low-middle-income international countries as donations.

 

While the firm-fixed-price agreement was ongoing, ACC procured an additional 300 million doses of COVID-19 vaccines on January 19, 2022. This modification deal was valued at $2 billion and concluded on September 30, 2022.

 

About Pfizer Inc.

 

Pfizer Inc. is one of the leading pharmaceutical companies in the world. Founded in 1849 by Charles Pfizer and his cousin Charles Erhart, Pfizer commits to “change patients’ lives” through developing and distributing medicines, vaccines, and other pharmaceutical products.

 

Recently, Pfizer ushered in the development of vaccines and treatments for the COVID-19 pandemic. To date, Pfizer has administered more than a billion doses of its mRNA vaccine to COVID-19 patients in the United States and worldwide.

 

Through government contracts signed by Pfizer executives and leaders, the pharmaceutical giant is able to bolster its partnership with multiple federal agencies that enable disease control through high-quality treatments to patients across the globe.